Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

D Wang; Y GUO; S A Wrighton; G E Cooke; W Sadée

doi:10.1038/tpj.2010.28

journal article Apr 13, 2010

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

D Wang Y GUO

S A Wrighton G E Cooke W Sadée

The Pharmacogenomics Journal Vol. 11 No. 4 pp. 274-286 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/tpj.2010.28

Topics

No keywords indexed for this article. Browse by subject →

References

58

[1]

Danielson PB . The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 2002; 3: 561–597. 10.2174/1389200023337054

[2]

Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 2003; 31: 755–761. 10.1124/dmd.31.6.755

[3]

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

T Shimada, H Yamazaki, M Mimura et al.

The Journal of Pharmacology and Experimental Thera... 1994 10.1016/s0022-3565(25)22379-5

[4]

Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M . Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 1999; 259: 201–205. 10.1006/bbrc.1999.0752

[5]

Lamba JK, Lin YS, Schuetz EG, Thummel KE . Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271–1294. 10.1016/s0169-409x(02)00066-2

[6]

Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10: 373–388. 10.1097/00008571-200007000-00001

[7]

Lamba J, Lamba V, Strom S, Venkataramanan R, Schuetz E . Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 2008; 36: 169–181. 10.1124/dmd.107.016600

[8]

He P, Court MH, Greenblatt DJ, von Moltke LL . Human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity. J Clin Pharmacol 2006; 46: 1356–1369. 10.1177/0091270006292125

[9]

Lamba J, Lamba V, Schuetz E . Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 2005; 6: 369–383. 10.2174/1389200054633880

[10]

Takagi S, Nakajima M, Mohri T, Yokoi T . Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 2008; 283: 9674–9680. 10.1074/jbc.m709382200

[11]

Pan YZ, Gao W, Yu AM . MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 2009; 37: 2112–2117. 10.1124/dmd.109.027680

[12]

Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB . Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90: 1225–1229. 10.1093/jnci/90.16.1225

[13]

Wojnowski L, Kamdem LK . Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol 2006; 2: 171–182. 10.1517/17425255.2.2.171

[14]

Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12: 121–132. 10.1097/00008571-200203000-00006

[15]

Garcia-Martin E, Martinez C, Pizarro RM, Garcia-Gamito FJ, Gullsten H, Raunio H et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther 2002; 71: 196–204. 10.1067/mcp.2002.121371

[16]

Amirimani B, Walker AH, Weber BL, Rebbeck TR . RESPONSE: remodification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1999; 91: 1588–1590. 10.1093/jnci/91.18.1588

[17]

Spurdle AB, Goodwin B, Hodgson E, Hopper JL, Chen X, Purdie DM et al. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 2002; 12: 355–366. 10.1097/00008571-200207000-00003

[18]

Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 1999; 66: 288–294. 10.1016/s0009-9236(99)70037-8

[19]

Zeigler-Johnson C, Friebel T, Walker AH, Wang Y, Spangler E, Panossian S et al. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res 2004; 64: 8461–8467. 10.1158/0008-5472.can-04-1651

[20]

Miao J, Jin Y, Marunde RL, Kim S, Quinney S, Radovich M et al. Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. Pharmacogenomics J 2009; 9: 319–326. 10.1038/tpj.2009.21

[21]

Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383–391. 10.1038/86882

[22]

Matsumura K, Saito T, Takahashi Y, Ozeki T, Kiyotani K, Fujieda M et al. Identification of a novel polymorphic enhancer of the human CYP3A4 gene. Mol Pharmacol 2004; 65: 326–334. 10.1124/mol.65.2.326

[23]

Perera MA, Thirumaran RK, Cox NJ, Hanauer S, Das S, Brimer-Cline C et al. Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans. Pharmacogenomics J 2009; 9: 49–60. 10.1038/tpj.2008.13

[24]

Schirmer M, Rosenberger A, Klein K, Kulle B, Toliat MR, Nurnberg P et al. Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics 2007; 8: 443–453. 10.2217/14622416.8.5.443

[25]

Hirota T, Ieiri I, Takane H, Maegawa S, Hosokawa M, Kobayashi K et al. Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status. Hum Mol Genet 2004; 13: 2959–2969. 10.1093/hmg/ddh313

[26]

Shitara Y, Sugiyama Y . Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006; 112: 71–105. 10.1016/j.pharmthera.2006.03.003

[27]

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)

Peter H Jones, Michael H Davidson, Evan A Stein et al.

The American Journal of Cardiology 2003 10.1016/s0002-9149(03)00530-7

[28]

Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 2005; 78: 551–558. 10.1016/j.clpt.2005.08.003

[29]

Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ . CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol 2004; 93: 104–107. 10.1016/j.amjcard.2003.08.078

[30]

Gao Y, Zhang LR, Fu Q . CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur J Clin Pharmacol 2008; 64: 877–882. 10.1007/s00228-008-0502-x

[31]

Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH . Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol Drug Saf 2010; 19: 75–81. 10.1002/pds.1866

[32]

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

Scott M. Grundy, James I. Cleeman, C. Noel Bairey Merz et al.

Journal of the American College of Cardiology 2004 10.1016/j.jacc.2004.07.001

[33]

Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W . Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 2005; 15: 693–704. 10.1097/01.fpc.0000178311.02878.83

[34]

Pinsonneault J, Nielsen CU, Sadee W . Genetic variants of the human H+/dipeptide transporter PEPT2: analysis of haplotype functions. J Pharmacol Exp Ther 2004; 311: 1088–1096. 10.1124/jpet.104.073098

[35]

A simple salting out procedure for extracting DNA from human nucleated cells

S.A. Miller, D.D. Dykes, H.F. Polesky

Nucleic Acids Research 1988 10.1093/nar/16.3.1215

[36]

Dai Z, Papp AC, Wang D, Hampel H, Sadee W . Genotyping panel for assessing response to cancer chemotherapy. BMC Med Genomics 2008; 1: 24. 10.1186/1755-8794-1-24

[37]

Papp AC, Pinsonneault JK, Cooke G, Sadee W . Single nucleotide polymorphism genotyping using allele-specific PCR and fluorescence melting curves. Biotechniques 2003; 34: 1068–1072. 10.2144/03345dd03

[38]

Leeder JS, Gaedigk R, Marcucci KA, Gaedigk A, Vyhlidal CA, Schindel BP et al. Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther 2005; 314: 626–635. 10.1124/jpet.105.086504

[39]

Kolwankar D, Vuppalanchi R, Ethell B, Jones DR, Wrighton SA, Hall SD et al. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol 2007; 5: 388–393. 10.1016/j.cgh.2006.12.021

[40]

Giacopelli F, Rosatto N, Divizia MT, Cusano R, Caridi G, Ravazzolo R . The first intron of the human osteopontin gene contains a C/EBP-beta-responsive enhancer. Gene Expr 2003; 11: 95–104. 10.3727/000000003108748991

[41]

Hugo H, Cures A, Suraweera N, Drabsch Y, Purcell D, Mantamadiotis T et al. Mutations in the MYB intron I regulatory sequence increase transcription in colon cancers. Genes Chromosomes Cancer 2006; 45: 1143–1154. 10.1002/gcc.20378

[42]

Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadee W . Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 2008; 112: 1013–1021. 10.1182/blood-2008-03-144899

[43]

Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003; 38: 978–988. 10.1002/hep.1840380424

[44]

Vyhlidal CA, Gaedigk R, Leeder JS . Nuclear receptor expression in fetal and pediatric liver: correlation with CYP3A expression. Drug Metab Dispos 2006; 34: 131–137. 10.1124/dmd.105.005967

[45]

Goodwin B, Redinbo MR, Kliewer SA . Regulation of cyp3a gene transcription by the pregnane x receptor. Annu Rev Pharmacol Toxicol 2002; 42: 1–23. 10.1146/annurev.pharmtox.42.111901.111051

[46]

Michlewski G, Sanford JR, Caceres JF . The splicing factor SF2/ASF regulates translation initiation by enhancing phosphorylation of 4E-BP1. Mol Cell 2008; 30: 179–189. 10.1016/j.molcel.2008.03.013

[47]

Lemaire R, Prasad J, Kashima T, Gustafson J, Manley JL, Lafyatis R . Stability of a PKCI-1-related mRNA is controlled by the splicing factor ASF/SF2: a novel function for SR proteins. Genes Dev 2002; 16: 594–607. 10.1101/gad.939502

[48]

Baralle M, Pastor T, Bussani E, Pagani F . Influence of Friedreich ataxia GAA noncoding repeat expansions on pre-mRNA processing. Am J Hum Genet 2008; 83: 77–88. 10.1016/j.ajhg.2008.06.018

[49]

Buratti E, Brindisi A, Pagani F, Baralle FE . Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: a functional link with disease penetrance. Am J Hum Genet 2004; 74: 1322–1325. 10.1086/420978

[50]

Grabczyk E, Usdin K . The GAA*TTC triplet repeat expanded in Friedreich's ataxia impedes transcription elongation by T7 RNA polymerase in a length and supercoil dependent manner. Nucleic Acids Res 2000; 28: 2815–2822. 10.1093/nar/28.14.2815

Showing 50 of 58 references

Cited By

398

Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report

Mercè Brunet, Teun van Gelder · 2019

Therapeutic Drug Monitoring

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

Ulrich M. Zanger, Matthias Schwab · 2013

Pharmacology & Therapeutics

From gut to kidney: Transporting and metabolizing calcineurin-inhibitors in solid organ transplantation

Noel Knops, Elena Levtchenko · 2013

International Journal of Pharmaceut...

Metrics

398

Citations

58

References

Details

Published: Apr 13, 2010
Vol/Issue: 11(4)
Pages: 274-286
License: View

Authors

D

D Wang

From the *David Geffen School of Medicine at UCLA, †Fielding School of Public Health, Department of Epidemiology, and ‡Fielding School of Public Health, Department of Biostatistics, UCLA, Los Angeles, CA

Cite This Article

D Wang, Y GUO, S A Wrighton, et al. (2010). Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. The Pharmacogenomics Journal, 11(4), 274-286. https://doi.org/10.1038/tpj.2010.28

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

You May Also Like